BUZZ - Kodiak Sciences shares rise as its eye disease drug meets clinical trial targets
路透社2026/09/28 10:56September 28 - ** The pharmaceutical company Kodiak Sciences (stock code: KOD.O) saw its share price rise by 43.9% in pre-market trading to $46.56
** The company stated that its experimental drugs Zenkuda and tabirafusp-ted achieved their primary endpoints in a late-stage clinical trial for patients with wet age-related macular degeneration
** Both drugs led to improvements in vision at one year, with efficacy not inferior to the comparator drug aflibercept
** Wet age-related macular degeneration results in abnormal leakage from blood vessels under the retina, which could result in loss of central vision
** Approximately 54% of Zenkuda patients achieved six-month dosing intervals, potentially reducing the number of required intravitreal injections
** The overall safety profile of both drugs was consistent with aflibercept; Kodiak Sciences plans further analysis to identify which patients may benefit most from tabirafusp-ted
** The company plans to apply for US marketing approval for Zenkuda in Q4 2026, based on five successful late-stage clinical trials in three retinal diseases
** As of the previous trading day's close, KOD was up 15.7% year-to-date
(To assist non-native English speakers, Reuters has automated the translation of its report into several other languages. As automated translation may contain errors or lack required context, Reuters does not guarantee the accuracy of the automated translation. The automated translation is provided solely for reader convenience. Reuters will not accept any liability for any damage or loss caused by the use of automated translation.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
After Jensen's resignation, the "Big Short" doubles down on shorting tech stocks! Warns the AI boom may turn into a "bull trap"
Michael Burry increased his short positions following Huang Renxun's resignation. He compared Nasdaq’s October peak to the top of the 2000 internet bubble. On November 12th, he doubled his put option positions on the Nasdaq 100, with expiry set for early 2027, and rebuilt put options on the VanEck Semiconductor Index. He directly warned investors to "exit the market" and predicted a significant correction in chip stocks before mid-2027.
Tesla (TSLA.US) Cybercab limited pre-orders open: priced at $29,990, with an additional monthly operating fee of $299
According to reports, Tesla has invited select customers to reserve the Cybercab, taking a step toward launching this self-driving model to general consumers.
Fed Vice Chair Sets the Tone: Inflation Is the "Most Important Signal," Interest Rate Decisions Depend on It
Federal Reserve Vice Chair Philip Jefferson stated that when policymakers consider whether to raise interest rates further, inflation has become the most important metric.
Elon Musk Leads Petition! Silicon Valley Supports Jensen Huang as Tens of Thousands Call for the Return of the Founder
Elon Musk has publicly co-signed a petition in support of Jensen Huang’s return to NVIDIA. The number of signatures on the petition website has surpassed 14,000, causing the site to almost crash due to a surge in traffic. What is raising further alarm in the capital markets is that NVIDIA’s core engineers have made collective statements, warning that if senior management mishandles the situation, key technical talent may leave, potentially undermining NVIDIA’s competitive moat.
Crypto prices
More
